KRASG12C IN-17 is an orally active covalent inhibitor targeting the KRASG12C mutation. It demonstrates potent inhibitory effects on KRASG12C-mutant cancer cell lines, with IC50 values of 0.7 nM in NCI-H23 and 0.5 nM in NCI-H358. This compound irreversibly binds to KRASG12C, achieving over 96% modification efficiency in both GDP-bound and GMPPNP-bound states. KRASG12C IN-17 is valuable for research focused on KRAS-driven malignancies, particularly in the context of colorectal cancer.
KRASG12C IN-17 is an orally active covalent inhibitor targeting the KRASG12C mutation. It demonstrates potent inhibitory effects on KRASG12C-mutant cancer cell lines, with IC50 values of 0.7 nM in NCI-H23 and 0.5 nM in NCI-H358. This compound irreversibly binds to KRASG12C, achieving over 96% modification efficiency in both GDP-bound and GMPPNP-bound states. KRASG12C IN-17 is valuable for research focused on KRAS-driven malignancies, particularly in the context of colorectal cancer.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
